FIGURE 6 from Activity of the Ubiquitin-activating Enzyme Inhibitor TAK-243 in Adrenocortical Carcinoma Cell Lines, Patient-derived Organoids, and Murine Xenografts

NCATS screening for synergistic drug combinations with TAK-243 in the CU-ACC1 and NCI-H295R cell lines. One hundred and seven drugs were tested in combination with TAK-243. A, Overall result of the screen with drugs listed in ExcessHSA order. The BCL2 inhibitors (S55746, Navitoclax and Venetoclax) and the mTOR inhibitors (Everolimus and Vistusertib) were indicated as red dots. B and C, Independent validation of the NCATS data for the BCL2 and mTOR inhibitors. ACC cell lines were treated with TAK-243 at the specified concentrations for 72 hours with or without Venetoclax (B) and Everolimus (C). Cell viability was assessed by CellTiter-Glo. Error bars represent SD of triplicates; CI values were also plotted.